Omburtamab I-131 - Y-mAbs Therapeutics

Drug Profile

Omburtamab I-131 - Y-mAbs Therapeutics

Alternative Names: 131 I-8H9; 8H9 MAb; 131I 8H9 (B7-H3); Burtomab I-131; Iodine I 131 monoclonal antibody 8H9; Mab 131-I labelled 8H9

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Y-mAbs Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Carcinomatous meningitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Carcinomatous meningitis; Neuroblastoma
  • Phase I/II Soft tissue sarcoma
  • No development reported Peritoneal cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Peritoneal-cancer(Recurrent, Second-line therapy or greater) in USA (Intraperitoneal)
  • 12 Sep 2017 Y-mAbs Therapeutics plans a phase II trial for Neuroblastoma (In children, In adolescents, In adults) (NCT03275402)
  • 07 Jun 2017 Burtomab -I-131 - Y-mAbs Therapeutics receives Breakthrough Therapy status for Neuroblastoma (Second-line therapy or greater, Metastatic disease, In neonates, In infants, In children) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top